Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovery, development, and commercialization of small molecule medicines for the treatment of viral diseases and cancer. Its clinical development programs primarily include ANA380 for the treatment of HBV. It also develops ANA773, an oral TLR-7 prodrug agonist, for the treatment of certain cancers; and AN 025-1, a series of non-nucleoside NS5B polymerase inhibitors, for the treatment of chronic HCV infection. It has drug discovery collaboration with Hoffmann-La Roche, Inc.; Aphoenix, Inc. to discover and advance lead compounds against Aphoenix targets for multiple therapeutic indications; and Valeant Pharmaceuticals International for licensing of antiviral compounds. The company was founded as ScripTech Pharmaceuticals, Inc. in 1992 and changed its name to Scriptgen Pharmaceuticals, Inc. in 1994. Later, it changed its name to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals, Inc. is headquartered in San Diego, California.